Holen Sie sich die Stockscreener-App
23.78
2.78%
-0.68
Schlusskurs vom Vortag:
$24.46
Offen:
$23.95
24-Stunden-Volumen:
1.05M
Relative Volume:
1.29
Marktkapitalisierung:
$1.44B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-170.19M
KGV:
-7.798
EPS:
-3.0495
Netto-Cashflow:
$-154.68M
1W Leistung:
-3.22%
1M Leistung:
+49.65%
6M Leistung:
+57.38%
1J Leistung:
-30.02%
1-Tages-Spanne:
$22.42
$24.45
1-Wochen-Bereich:
$22.42
$25.05
52-Wochen-Spanne:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
23.78 | 1.90B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Can a trend reversal in Spyre Therapeutics Inc. lead to recoveryMarket Sentiment Summary & Long-Term Safe Investment Ideas - newser.com
What sentiment indicators say about Spyre Therapeutics Inc. stockJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
Why retail investors favor Spyre Therapeutics Inc. stock2025 Bull vs Bear & AI Powered Market Trend Analysis - newser.com
Is Spyre Therapeutics Inc. stock a buy for dividend growth2025 Big Picture & Free High Return Stock Watch Alerts - newser.com
Is a relief rally coming for Spyre Therapeutics Inc. holdersJuly 2025 Sentiment & Risk Controlled Stock Pick Alerts - newser.com
What insider purchases suggest about Spyre Therapeutics Inc. (3920) stockMarket Movers & AI Driven Stock Reports - newser.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulationPortfolio Profit Report & Expert Verified Movement Alerts - newser.com
Why Spyre Therapeutics Inc. stock is seen as undervaluedWeekly Investment Report & Precise Swing Trade Entry Alerts - newser.com
Using data tools to time your Spyre Therapeutics Inc. exitJuly 2025 Selloffs & Smart Swing Trading Techniques - newser.com
What dividend safety score for Spyre Therapeutics Inc. stockChart Signals & Free Accurate Trade Setup Notifications - newser.com
Can Spyre Therapeutics Inc. stock sustain free cash flow growthShare Buyback & AI Powered Market Entry Strategies - newser.com
Using Ichimoku Cloud for Spyre Therapeutics Inc. technicalsEarnings Overview Report & Weekly High Potential Stock Alerts - newser.com
Will Spyre Therapeutics Inc. (3920) stock beat international competitionMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Will Spyre Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Highlights & Smart Swing Trading Alerts - newser.com
Will Spyre Therapeutics Inc. (3920) stock sustain uptrend momentumStop Loss & Expert Verified Movement Alerts - newser.com
Is Spyre Therapeutics Inc. (3920) stock undervalued after correction2025 Price Momentum & Consistent Growth Stock Picks - newser.com
Will Spyre Therapeutics Inc. stock maintain dividend yieldMarket Performance Summary & Weekly High Potential Alerts - newser.com
Will Spyre Therapeutics Inc. stock sustain high P E ratiosMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com
Is Spyre Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Why Spyre Therapeutics Inc. stock remains on watchlistsPortfolio Risk Report & Real-Time Market Trend Scan - newser.com
How to escape a deep drawdown in Spyre Therapeutics Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
Will Spyre Therapeutics Inc. stock recover faster than peers2025 EndofYear Setup & Growth Focused Stock Reports - newser.com
Published on: 2025-11-02 03:35:20 - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilient2025 Analyst Calls & Risk Managed Investment Signals - newser.com
Why Spyre Therapeutics Inc. stock remains undervalued2025 AllTime Highs & Smart Allocation Stock Tips - newser.com
Earnings visualization tools for Spyre Therapeutics Inc.July 2025 Patterns & Community Consensus Trade Alerts - newser.com
Published on: 2025-11-01 04:11:34 - newser.com
Spyre Therapeutics (SYRE) to Release Quarterly Earnings on Thursday - MarketBeat
What drives Spyre Therapeutics Inc 3920 stock priceInsider Buying Signals & Free Professional Investment Consultations - earlytimes.in
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):